Obsessive-compulsive disorder affects roughly one in 40 adults in the United States, and for a meaningful portion of those people, the first-line treatments medication and cognitive behavioral therapy do not produce adequate relief (National Institute of Mental Health). That gap between what standard care can offer and what patients actually need is not a failure of effort or willpower. It is a clinical reality with biological roots, and it has biological solutions. At The Mood Center in Annapolis and Columbia, Maryland, we work with patients whose OCD has not responded to conventional approaches, and we think the most useful thing we can do is help them understand what treatment resistance actually means and what options exist.
What Treatment-Resistant OCD Actually Means
OCD obsessive-compulsive disorder is characterized by persistent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) that a person feels driven to perform in response to those thoughts. The compulsions are typically aimed at reducing distress or preventing a feared outcome, even when the person recognizes that the behavior is excessive or disconnected from the actual threat (National Institute of Mental Health). This distinction matters clinically: OCD is not simply anxiety or excessive worry. It is a specific pattern of thought-response cycling that operates through its own neural circuitry. For a broader overview of how these symptoms present and what treatment paths are available, see our guide to OCD symptoms and treatment paths explained.
The standard treatment approach combines serotonin reuptake inhibitor medications typically SSRIs at doses higher than those used for depression with a specialized form of cognitive behavioral therapy called exposure and response prevention, or ERP. For many patients, this combination is effective. For others, it is not. Treatment-resistant OCD is generally understood as OCD that has not responded adequately to at least two adequate trials of SSRI medication, with or without psychotherapy.
What makes OCD resistant in some patients is not fully understood, but research increasingly points to neurological circuits beyond the serotonin system particularly the cortico-striato-thalamo-cortical loop, a circuit that connects the prefrontal cortex to deeper brain structures involved in habit formation and threat detection. When this circuit is dysregulated, it produces the stuck-gear quality that many patients with OCD describe: the intrusive thought arrives, the compulsion fires, the distress does not resolve, and the cycle repeats regardless of conscious effort to stop it. Serotonin-targeted medication addresses part of this circuitry. For patients whose resistance runs deeper, additional approaches may be needed.
How Ketamine May Help When SSRIs Haven’t
Ketamine works through the glutamate system rather than the serotonin system, targeting NMDA receptors N-methyl-D-aspartate receptors that play a role in the neural circuits involved in OCD’s compulsive patterns. Research highlighted by the National Institutes of Health identifies ketamine as one of the treatments showing promise specifically for patients with OCD who have not responded to standard therapies. The rapid action of ketamine producing effects within hours rather than weeks is particularly relevant for patients who have spent years cycling through medication trials without finding relief.
At our clinic, IV ketamine is administered intravenously over 45 minutes in a private, medically supervised setting. Our standard protocol for mood and psychiatric conditions consists of six infusions over three weeks, with booster sessions available monthly or as needed after the initial course. Results vary by individual, and we conduct a thorough clinical evaluation before recommending any treatment to ensure that IV ketamine is an appropriate fit for your specific history and presentation.
The neuroplasticity that ketamine promotes the brain’s capacity to form new connections and reorganize maladaptive circuits may also be relevant to OCD specifically. If the cortico-striato-thalamo-cortical loop driving compulsive behavior has been reinforced over years of repeated cycling, a treatment that actively promotes neural reorganization offers a different kind of intervention than one that simply adjusts neurotransmitter availability. This is an area of active research, and we are careful to represent it accurately: the evidence is promising, and it is early enough that we present it as potential rather than certainty. You can learn more on our dedicated ketamine for OCD page.
The Role of TMS in Treatment-Resistant OCD
Transcranial magnetic stimulation TMS is the only non-medication, non-invasive treatment with FDA clearance specifically for OCD, in addition to its existing clearance for major depressive disorder. TMS uses a magnetic coil positioned near the scalp to deliver focused magnetic pulses to targeted brain regions. For OCD, the treatment targets areas of the prefrontal cortex involved in the dysregulated circuitry that drives obsessive-compulsive patterns (FDA).
The FDA permitted marketing of TMS specifically for OCD based on clinical evidence demonstrating its effectiveness for patients whose condition had not responded adequately to medication. This is significant: TMS for OCD is not an off-label application. It is an FDA-cleared indication, which also means it is covered by most major insurance plans for patients who meet the clinical criteria. For a closer look at the mechanisms and patient experience, our dedicated page on TMS for OCD covers how the treatment targets OCD’s neural circuitry and what patients can expect.
At our clinic, TMS is delivered using Magstim® technology, which offers multiple protocols including ultra-short sessions as brief as three minutes. The standard course involves sessions five days per week for approximately six to seven weeks, with an initial mapping session to calibrate the treatment to your individual neurology. Patients remain fully awake and alert throughout every session, can drive themselves to and from appointments, and continue their normal routines between treatments. There is no sedation, no systemic medication, and no recovery period. For a deeper look at how this treatment works and what patients can expect, our overview of TMS for OCD covers the mechanism, the evidence, and the patient experience in detail.
For patients with treatment-resistant OCD, the combination of TMS and ketamine may produce faster and more comprehensive results than either treatment alone. We discuss this option with patients for whom a combined approach may be clinically appropriate.
Recognizing the Signs That Standard Treatment Has Stopped Working
One of the more difficult aspects of treatment-resistant OCD is knowing when to recognize that the current approach has run its course. Patients often stay with a treatment longer than they should, uncertain whether they simply need more time or whether the treatment is genuinely not working. A few patterns are worth discussing with your provider. If you have completed at least two adequate SSRI trials meaning full therapeutic doses for a sufficient duration and have not experienced meaningful symptom reduction, that meets a reasonable clinical threshold for exploring additional options. If your OCD has remained stable or worsened despite consistent engagement with therapy and medication, that pattern is also clinically informative. And if the burden of OCD is significantly limiting your work, relationships, or daily function despite active treatment, that functional impact is itself a signal that the current approach needs to be reconsidered.
None of this means giving up on what has helped partially. Many patients who pursue ketamine or TMS continue medication and therapy alongside these treatments. The goal is not replacement but augmentation adding an approach that addresses the parts of OCD’s neurobiology that SSRIs and ERP are not fully reaching.
Addressing What Keeps People from Seeking Further Help
Stigma is a genuine barrier for many people with OCD. The condition is frequently misrepresented in popular culture as a quirk or a preference for orderliness, which does not capture the clinical reality of intrusive, distressing, unwanted thoughts and the compulsive behaviors they generate. Patients sometimes feel that their symptoms will not be taken seriously, or that seeking a more intensive treatment option marks them as more severely ill than they want to acknowledge. We want to name that directly: treatment-resistant OCD is a recognized clinical category, not a judgment about severity of character. Pursuing additional options when standard treatment has not worked is a medically appropriate and clinically supported decision.
Cost and insurance access are practical concerns that deserve a direct answer. TMS for OCD is covered by most major insurance plans for patients who meet criteria, and we are in-network with CareFirst, Anthem, Aetna, Cigna, United Healthcare, Tricare, Maryland Medicaid, and Medicare our team handles prior authorization on your behalf. IV ketamine is self-pay and not currently covered by insurance; it is $425 per session, or $395 per session when purchasing a package of 6, which is our standard initial course. Patient financing is available for those who need it, and we walk through the complete financial picture during your consultation before you make any commitments.
Frequently Asked Questions
How do I know if my OCD is treatment-resistant? A general clinical threshold is inadequate response to at least two adequate SSRI trials meaning full therapeutic doses maintained for a sufficient duration. If you have also engaged consistently with cognitive behavioral therapy, particularly exposure and response prevention, and have not seen meaningful improvement, that further supports exploring additional options. Discuss your full treatment history with a qualified provider to get a clear picture of where you stand.
Is ketamine for OCD FDA-approved? Ketamine for OCD is not currently FDA-approved for that specific indication, but it is an area of active clinical investigation with promising research highlighted by the National Institutes of Health. TMS, by contrast, has received FDA clearance specifically for OCD and is the non-medication treatment with the strongest regulatory standing for this condition. We discuss both options honestly, including what the evidence supports and where it is still developing.
Can I continue my current OCD medications while pursuing ketamine or TMS? Yes. We do not discontinue patient-prescribed medications as part of our treatment protocols, and both ketamine and TMS can generally be used alongside existing medication regimens. Your individual circumstances will guide how we approach any adjustments. Discuss your current medications with our team during the evaluation process.
Do you treat OCD at both your Annapolis and Columbia locations? Yes. We offer IV ketamine and TMS at both our Annapolis and Columbia, Maryland locations. Evening and Saturday appointments are available at both locations to accommodate patients who cannot take time off during standard work hours.
What does the free consultation involve? Our free consultation is a conversation not a commitment. We will review your treatment history, discuss your symptoms and what you have already tried, explain the options we think may be clinically appropriate for your situation, and answer your questions about the treatment process, costs, and insurance coverage. You leave with a clearer picture of your options and no obligation to proceed.
Key Takeaways
Treatment-resistant OCD is defined by inadequate response to at least two adequate SSRI trials and is a recognized clinical category with evidence-based next steps, not a dead end.
Ketamine works through the glutamate system rather than serotonin, targeting neural circuits involved in OCD that standard antidepressants do not directly address, and is identified by the National Institutes of Health as a promising option for patients with OCD who have not responded to standard treatments.
TMS has received FDA clearance specifically for OCD and is covered by most major insurance plans for patients who meet criteria a non-invasive, drug-free option with a well-established evidence base.
A combined approach using both ketamine and TMS may be appropriate for some patients and is something we discuss when clinically indicated.
Results vary by individual, and all treatment decisions at The Mood Center are made collaboratively based on your full history, not a one-size-fits-all protocol.
When standard OCD treatment has not produced the relief you need, that history is clinical information not a verdict on what is possible. We offer free consultations at both our Annapolis and Columbia locations, with evening and Saturday appointments available for patients managing full schedules. Call us at 443-940-MOOD or schedule online to have a direct conversation about whether ketamine therapy, TMS, or a combination approach may be appropriate for where you are right now.
References
National Institute of Mental Health. What is OCD. https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd
National Institutes of Health. Ketamine for OCD. https://nihrecord.nih.gov/2023/01/06/new-treatments-ocd-show-promise
FDA. TMS FDA approval for OCD. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for OCD, including ketamine therapy and TMS, should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Individual results vary. The treatment descriptions in this article represent general clinical information and do not constitute a guarantee of outcomes for any specific patient. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
